Nanocarriers are embryonic contenders (act as a carrier to target drug in mucosal site) for the delivery of antigen through the mucosal route. Oral routes are preferred over the conventional route for immunization because it produces systemic mucosal immunity. Advanced forms of Nanocarriers elicit the stability of antigen into the GIT, simulated gastric fluid, and simulated intestinal fluid. In the present study, Mannosylated blossoms were developed and evaluated for their morphology, entrapment efficiency by using central composite design (DoE). The formulation showed more stability as compared to conventional Nanocarriers (liposome, niosomes, etc). Mannosylation influences dendritic cell targeting. It also improves the acid degradation of antigen in GIT as well as elicits the mucosal immune response. Our objective of this research is the preparation, of tetanus toxoid loaded bilosomes that target the mucosal site where dendritic cells are present. Bilosomes were prepared by the film hydration method and optimization of bilosomes was done to get the desired vesicle size and maximum encapsulation efficiency. Optimization of bilosomes was done to get the desired vesicle size and maximum encapsulation efficiency. The developed nanocarriers system was found to be stable in the gastrointestinal tract and suitable for the delivery of antigen to the intestine as compared to the conventional nanocarriers. Invivo study reveals that nanocarriers i.e. mannosylated bilosomes enable to protect antigen in a raucous gastric environment and elicit both systemic and humoral immunity. The immunological assay shows that mice immunized with antigen-loaded mannosylated bilosomes display a high concentration of IgG that indicates the successful antigen delivery through oral route. Oral vaccine formulation provides vast protection than the parenteral route.

REFERENCE

1.       Finkelstein P, Teisch L, Allen CJ, Ruiz G. Tetanus: a potential public health threat in times of disaster. Prehosp Disaster Med. 2017 Jun 1;32(3):339-42. doi: 10.1017/S1049023X17000012, PMID 28215195.

2.       Vela Ramirez JE, Sharpe LA, Peppas NA. Current state and challenges in developing oral vaccines. Adv Drug Deliv Rev. 2017 May 15;114:116-31. doi: 10.1016/j.addr.2017.04.008, PMID 28438674.

3.       De Magistris MT. Mucosal delivery of vaccine antigens and its advantages in pediatrics. Adv Drug Deliv Rev. 2006 Apr 20;58(1):52-67. doi: 10.1016/j.addr.2006.01.002, PMID 16516335.

4.       Sahu KK, Pandey RS. Development and characterization of HBsAg-loaded Eudragit nanoparticles for effective colonic immunization. Pharm Dev Technol. 2019 Feb 7;24(2):166-75. doi: 10.1080/10837450.2018.1444639, PMID 29468926.

5.       Azegami T, Yuki Y, Kiyono H. Challenges in mucosal vaccines for the control of infectious diseases. Int Immunol. 2014 Sep 1;26(9):517-28. doi: 10.1093/intimm/dxu063, PMID 24914172.

6.       Srivastava A, Gowda DV, Madhunapantula SV, Shinde CG, Iyer M. Mucosal vaccines: a paradigm shift in the development of mucosal adjuvants and delivery vehicles. APMIS. 2015 Apr;123(4):275-88. doi: 10.1111/apm.12351, PMID 25630573.

7.       Nizard M, Diniz MO, Roussel H, Tran T, Ferreira LC, Badoual C, Tartour E. Mucosal vaccines: novel strategies and applications for the control of pathogens and tumors at mucosal sites. Hum Vaccin Immunother. 2014 Aug 1;10(8):2175-87. doi: 10.4161/hv.29269, PMID 25424921.

8.       Arora D, K. Goyal A, R. Paliwal S, Khurana B, P. Vyas S. Oral mucosal immunization: recent advancement and future prospects. Curr Immunol Rev. 2010 Aug 1;6(3):234-59. doi: 10.2174/157339510791823637.

9.       Mills KHG. Recognition of foreign antigen by T cells and their role in immune protection. Curr Opin Infect Dis. 1989 Dec 1;2(6):804-14. doi: 10.1097/00001432-198912000-00014.

10.     Neela MC, Mills GH. Manipulating the immune system: humoral vs. cell mediated immunity. Adv Drug Deliv Rev. 2001:43-54.

11.     Van Ginkel FW, Nguyen HH, McGhee JR. Vaccines for mucosal immunity to combat emerging infectious diseases. Emerg Infect Dis. 2000 Mar;6(2):123-32. doi: 10.3201/eid0602.000204, PMID 10756145.

12.     Engels N, Wienands J. Memory control by the B cell antigen receptor. Immunol Res. 2018 May;283(1):150-60. doi: 10.1111/imr.12651, PMID 29664567.

13.     Cruvinel Wde M, Mesquita D, Araújo JA, Catelan TT, de Souza AW, da Silva NP, Andrade LE. Immune system - Part I. Fundamentals of innate immunity with emphasis on molecular and cellular mechanisms of inflammatory response. Rev Bras Reumatol. 2010;50(4):434-61. doi: 10.1590/S0482-50042010000400008, PMID 21125178.

14.     Delves PJ, Roitt IM. The immune system. First of two parts. N Engl J Med. 2000 Jul 6;343(1):37-49. doi: 10.1056/NEJM200007063430107, PMID 10882768.

15.     Mosser DM, Edwards JP. Exploring the full spectrum of macrophage activation. Nat Rev Immunol. 2008 Dec;8(12):958-69. doi: 10.1038/nri2448, PMID 19029990.

16.     Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, Pulendran B, Palucka K. Immunobiology of dendritic cells. Annu Rev Immunol. 2000 Apr;18(1):767-811. doi: 10.1146/annurev.immunol.18.1.767, PMID 10837075.

17.     Neutra MR, Kozlowski PA. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol. 2006 Feb;6(2):148-58. doi: 10.1038/nri1777, PMID 16491139.

18.     Cook IF. Evidence based route of administration of vaccines. Hum Vaccin. 2008 Jan 1;4(1):67-73. doi: 10.4161/hv.4.1.4747, PMID 17881890.

19.     Herzog C. Influence of parenteral administration routes and additional factors on vaccine safety and immunogenicity: a review of recent literature. Expert Rev Vaccines. 2014 Mar 1;13(3):399-415. doi: 10.1586/14760584.2014.883285, PMID 24512188.

20.     Irvine KR, Chamberlain RS, Shulman EP, Rosenberg SA, Restifo NP. Route of immunization and the therapeutic impact of recombinant anticancer vaccines. J Natl Cancer Inst. 1997 Mar 5;89(5):390-2. doi: 10.1093/jnci/89.5.390, PMID 9060962.

21.     Kozlowski PA, Cu-Uvin S, Neutra MR, Flanigan TP. Comparison of the oral, rectal, and vaginal immunization routes for induction of antibodies in rectal and genital tract secretions of women. Infect Immun. 1997 Apr 1;65(4):1387-94. doi: 10.1128/IAI.65.4.1387-1394.1997, PMID 9119478.

22.     Kosiewicz MM, Zirnheld AL, Alard P. Gut microbiota, immunity, and disease: a complex relationship. Front Microbiol. 2011;2:180. doi: 10.3389/fmicb.2011.00180, PMID 21922015.

23.     Levine MM. Immunogenicity and efficacy of oral vaccines in developing countries: lessons from a live cholera vaccine. BMC Biol. 2010 Dec;8(1):129. doi: 10.1186/1741-7007-8-129, PMID 20920375.

24.     Xu B, Zhang W, Chen Y, Xu Y, Wang B, Zong L. Eudragit® L100-coated mannosylated chitosan nanoparticles for oral protein vaccine delivery. Int J Biol Macromol. 2018 Jul 1;113:534-42. doi: 10.1016/j.ijbiomac.2018.02.016, PMID 29408613.

25.     Kim SH, Kim YN, Kim J, Jang YS. C5a receptor targeting of partial non-structural protein 3 of dengue virus promotes antigen-specific IFN-γ-producing T-cell responses in a mucosal dengue vaccine model. Cell Immunol. 2018 Mar 1;325:41-7. doi: 10.1016/j.cellimm.2018.01.016, PMID 29397905.

26.     Zhang R, Wang C, Cheng W, Duan G, Shi Q, Chen S, Fan Q. Delivery of Helicobacter pylori HpaA to gastrointestinal mucosal immune sites using Lactococcus lactis and its immune efficacy in mice. Biotechnol Lett. 2018 Mar 1;40(3):585-90. doi: 10.1007/s10529-017-2502-3, PMID 29299716.

27.     Nakahashi-Ouchida R, Yuki Y, Kiyono H. Development of a nanogel-based nasal vaccine as a novel antigen delivery system. Expert Rev Vaccines. 2017 Dec 2;16(12):1231-40. doi: 10.1080/14760584.2017.1395702, PMID 29053938.

28.     Vemireddy S, M C PP, Halmuthur M SK. Chitosan stabilized nasal emulsion delivery system for effective humoral and cellular response against recombinant tetravalent dengue antigen. Carbohydr Polym. 2018;190:129-38. doi: 10.1016/j.carbpol.2018.02.073, PMID 29628230.

29.     Lopes PD, Okino CH, Fernando FS, Pavani C, Casagrande VM, Lopez RFV, Montassier MFS, Montassier HJ. Inactivated infectious bronchitis virus vaccine encapsulated in chitosan nanoparticles induces mucosal immune responses and effective protection against challenge. Vaccine. 2018 May 3;36(19):2630-6. doi: 10.1016/j.vaccine.2018.03.065, PMID 29653848.

30.     Manjaly Thomas ZR, McShane H. Aerosol immunisation for TB: matching route of vaccination to route of infection. Trans R Soc Trop Med Hyg. 2015 Mar 1;109(3):175-81. doi: 10.1093/trstmh/tru206, PMID 25636950.

31.     Leiva-Juarez MM, Kirkpatrick CT, Gilbert BE, Scott B, Tuvim MJ, Dickey BF, Evans SE, Markesich D. Combined aerosolized toll-like receptor ligands are an effective therapeutic agent against influenza pneumonia when co-administered with oseltamivir. Eur J Pharmacol. 2018 Jan 5;818:191-7. doi: 10.1016/j.ejphar.2017.10.035, PMID 29066417.

32.     Díaz Ortega JL, Castaneda D, Arellano Quintanilla DM, Martínez D, Trumbo SP, Fernández de Castro J. Antibody persistence in children aged 6-7 years one year following booster immunization with two MMR vaccines applied by aerosol or by injection. Vaccine. 2017 May 25;35(23):3116-22. doi: 10.1016/j.vaccine.2017.04.027, PMID 28457672.

33.     Premjeet S, Sahil K. Transcutaneous drug delivery system: A comprehensive review. IRJP Rev. 2011;2(12):49-55.

34.     Wakabayashi R, Sakuragi M, Kozaka S, Tahara Y, Kamiya N, Goto M. Solid-in-oil peptide nanocarriers for transcutaneous cancer vaccine delivery against melanoma. Mol Pharm. 2018 Feb 5;15(3):955-61. doi: 10.1021/acs.molpharmaceut.7b00894, PMID 29397746.

35.     Lopez PA, Denny M, Hartmann AK, Alflen A, Probst HC, von Stebut E, Tenzer S, Schild H, Stassen M, Langguth P, Radsak MP. Transcutaneous immunization with a novel imiquimodnanoemulsion induces superior T cell responses and virus protection. J Dermatol Sci. 2017 Sep 1;87(3):252-9. doi: 10.1016/j.jdermsci.2017.06.012, PMID 28655469.

36.     Kraan H, Vrieling H, Czerkinsky C, Jiskoot W, Kersten G, Amorij JP. Buccal and sublingual vaccine delivery. J Control Release. 2014 Sep 28;190:580-92. doi: 10.1016/j.jconrel.2014.05.060, PMID 24911355.

37.     Hamman JH, Enslin GM, Kotzé AF. Oral delivery of peptide drugs: barriers and developments. BioDrugs. 2005 May 1;19(3):165-77. doi: 10.2165/00063030-200519030-00003, PMID 15984901.

38.     Engman H. Intestinal barriers to oral drug absorption: cytochrome P450 3A and ABC-Transport proteins (Doctoral dissertation, ActaUniversitatisUpsaliensis).

39.     Lin L, Wong H. Predicting oral drug absorption: mini review on physiologically-based pharmacokinetic models. Pharmaceutics. 2017;9(4). doi: 10.3390/pharmaceutics9040041, PMID 28954416.

40.     Renukuntla J, Vadlapudi AD, Patel A, Boddu SH, Mitra AK. Approaches for enhancing oral bioavailability of peptides and proteins. Int J Pharm. 2013 Apr 15;447(1-2):75-93. doi: 10.1016/j.ijpharm.2013.02.030, PMID 23428883.

41.     Bruno BJ, Miller GD, Lim CS. Basics and recent advances in peptide and protein drug delivery. Ther Deliv. 2013;4(11):1443-67. doi: 10.4155/tde.13.104, PMID 24228993.

42.     Khodabandehloo H, Zahednasab H, Ashrafi Hafez AA. Nanocarriers usage for drug delivery in cancer therapy. Iran J Cancer Prev. 2016 Apr;9(2):e3966. doi: 10.17795/ijcp-3966, PMID 27482328.

43.     Mody N, Sharma R, Agarwal U, vyas SP. Therapeutics delivery. Rev. 2015;6(2):231-45.

44.     Laborde RJ, Sanchez-Ferras O, Luzardo MC, Cruz-Leal Y, Fernández A, Mesa C, Oliver L, Canet L, Abreu-Butin L, Nogueira CV, Tejuca M, Pazos F, Álvarez C, Alonso ME, Longo-Maugéri IM, Starnbach MN, Higgins DE, Fernández LE, Lanio ME. Novel adjuvant based on the pore-forming protein sticholysin ii encapsulated into liposomes effectively enhances the antigen-specific CTL-mediated immune response. J Immunol. 2017 Apr 1;198(7):2772-84. doi: 10.4049/jimmunol.1600310, PMID 28258198.

45.     Alipour Talesh GA, Ebrahimi Z, Badiee A, Mansourian M, Attar H, Arabi L, Jalali SA, Jaafari MR. Poly(I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol Lett. 2016 Aug 1;176:57-64. doi: 10.1016/j.imlet.2016.05.016, PMID 27260485.

46.     Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. B acillus C almette–G uerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci. 2013 Jan;104(1):22-7.10.2147/RRU.S63447. doi: 10.1111/cas.12075.

47.     Le Moignic A, Malard V, Benvegnu T, Lemiègre L, Berchel M, Jaffrès PA, Baillou C, Delost M, Macedo R, Rochefort J, Lescaille G, Pichon C, Lemoine FM, Midoux P, Mateo V. Preclinical evaluation of mRNA trimannosylatedlipopolyplexes as therapeutic cancer vaccines targeting dendritic cells. J Control Release. 2018 May 28;278:110-21. doi: 10.1016/j.jconrel.2018.03.035, PMID 29630987.

48.     Nekkanti V, Kalepu S. Recent advances in liposomal drug delivery: a review. Pharm Nanotechnol. 2015 Mar 1;3(1):35-55. doi: 10.2174/2211738503666150709173905.

49.     Jadhav MS, Morey P, karpe M, Kadam V. Novel vesicular system: an overview, JAPS. Rev. 2012:193-202.

50.     Mohamed HB, El-Shanawany SM, Hamad MA, Elsabahy M. Niosomes: a strategy toward prevention of clinically significant drug incompatibilities [Sci Rep:6340]. Sci Rep. 2017 Jul 24;7(1):6340. doi: 10.1038/s41598-017-06955-w, PMID 28740102.

51.     Prasad V, Chaurasia S. Performance evaluation of non-ionic surfactant based tazarotene encapsulated proniosomal gel for the treatment of psoriasis. Mater Sci Eng C Mater Biol Appl. 2017 Oct 1;79:168-76. doi: 10.1016/j.msec.2017.05.036, PMID 28629004.

52.     Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development and in vitro/in vivo evaluation of controlled release provesicles of a nateglinide–maltodextrin complex. Acta pharmacol sin B. 2014 Oct 1;4(5):408-16. doi: 10.1016/j.apsb.2014.08.001, PMID 26579411.

53.     Abidin L, Mujeeb M, Imam SS, Aqil M, Khurana D. Enhanced transdermal delivery of luteolin via non-ionic surfactant-based vesicle: quality evaluation and anti-arthritic assessment. Drug Deliv. 2016 Mar 23;23(3):1079-84. doi: 10.3109/10717544.2014.945130, PMID 25116512.

54.     Maheshwari C, Pandey RS, Chaurasiya A, Kumar A, Selvam DT, Prasad GB, Dixit VK. Non-ionic surfactant vesicles mediated transcutaneous immunization against hepatitis B. Int Immunopharmacol. 2011 Oct 1;11(10):1516-22. doi: 10.1016/j.intimp.2011.05.007, PMID 21609785.

55.     Mann JF, Scales HE, Shakir E, Alexander J, Carter KC, Mullen AB, Ferro VA. Oral delivery of tetanus toxoid using vesicles containing bile salts (bilosomes) induces significant systemic and mucosal immunity. Methods. 2006 Feb 1;38(2):90-5. doi: 10.1016/j.ymeth.2005.11.002, PMID 16414269.

56.     Conacher M, Alexander J, Brewer JM. Oral immunisation with peptide and protein antigens by formulation in lipid vesicles incorporating bile salts (bilosomes). Vaccine. 2001 Apr 6;19(20-22):2965-74. doi: 10.1016/s0264-410x(00)00537-5, PMID 11282208.

57.     Arora DA, Khurana BH, Kumar MS, Vyas SP. Oral immunization against hepatitis B virus using mannosylatedbilosomes. Int J Recent Adv Pharm Res. 2011;1:45-51.

58.     Shukla A, Singh B, Katare OP. Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano?bilosomes. Br J Pharmacol. 2011 Sep 2;164(2b):820-7. doi: 10.1111/j.1476-5381.2011.01452.x, PMID 21506959.

59.     Singh P, Prabakaran D, Jain S, Mishra V, Jaganathan KS, Vyas SP. Cholera toxin B subunit conjugated bile salt stabilized vesicles (bilosomes) for oral immunization. Int J Pharm. 2004 Jul 8;278(2):379-90. doi: 10.1016/j.ijpharm.2004.03.014, PMID 15196642.

60.     Deepika B, Kumar MS. Development of Leishmania donovani antigen-loaded mannosylatedbilosomes to target M cell: in vitro characterization. World J Pharm Pharm Res Rev. 2014 Jun 10;3:1983-99. doi: 10.22270/jddt.v9i3.2861.

61.     Cao XX, Li YH, Ye QL, Hu X, Wang TF, Fan MW. Self-assembling anticaries mucosal vaccine containing ferritin cage nanostructure and glucan-binding region of S. mutansglucosyltransferase effectively prevents caries formation in rodents. Hum Vaccin Immunother. 2017 Oct 3;13(10):2332-40. doi: 10.1080/21645515.2017.1349046, PMID 28759297.

62.     Kaur M, Malik B, Garg T, Rath G, Goyal AK. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv. 2015 Apr 3;22(3):328-34. doi: 10.3109/10717544.2014.894594, PMID 24611942.

63.     Harde H, Agrawal AK, Jain S. Tetanus toxoids loaded glucomannosylated chitosan based nanohoming vaccine adjuvant with improved oral stability and immunostimulatory response. Pharm Res. 2015 Jan 1;32(1):122-34. doi: 10.1007/s11095-014-1449-5, PMID 25030184.

64.     Bielinska AU, Janczak KW, Landers JJ, Makidon P, Sower LE, Peterson JW, Baker JR. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun. 2007 Aug 1;75(8):4020-9. doi: 10.1128/IAI.00070-07, PMID 17502384.

65.     Makidon PE, Bielinska AU, Nigavekar SS, Janczak KW, Knowlton J, Scott AJ, Mank N, Cao Z, Rathinavelu S, Beer MR, Wilkinson JE, Blanco LP, Landers JJ, Baker JR. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLOS ONE. 2008 Aug 13;3(8):e2954. doi: 10.1371/journal.pone.0002954, PMID 18698426.

66.     Hämmerling U, Westphal O. Synthesis and use of O?stearoyl polysaccharides in passive hemagglutination and hemolysis. Eur J Biochem. 1967 Mar;1(1):46-50. doi: 10.1007/978-3-662-25813-2_9, PMID 6059348.

67.     Copland MJ, Baird MA, Rades T, McKenzie JL, Becker B, Reck F, Tyler PC, Davies NM. Liposomal delivery of antigen to human dendritic cells. Vaccine. 2003 Feb 14;21(9-10):883-90. doi: 10.1016/S0264-410X(02)00536-4, PMID 12547598.